News

vasopharm GmbH is pleased to announce that enrolment into the pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial is completed. vasopharm remains on track to deliver headline data by end of 2020.

vasopharm GmbH, a privately held biopharmaceutical company, today announced that following a safety and efficacy interim assessment conducted according to the clinical trial protocol by the Data Monitoring Committee (DMC) it has received the following recommendation:

50% of patients enrolled in trial triggers interim data review. vasopharm GmbH today announced that it has recruited half of the 220 patients in the ongoing, pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, regrets to announce that Dr Irina Antonijevic (CMO) will return to Boston as a result of a family health issue.

vasopharm GmbH today announced the completion of a Phase 1 safety study on its late stage asset, VAS203. This study was conducted in support of the ongoing pivotal Phase III (NOSTRA III) trial of moderate to severe traumatic brain injury, which is currently running in 25 European centres.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Dr Irina Antonijevic as Chief Medical Officer. In this newly-created role, Dr Antonijevic will be responsible for advancing the clinical development of vasopharm’s lead ongoing program, VAS203.